Targeting cancer cells: magnetic nanoparticles as drug carriers.
Magnetic drug targeting employing nanoparticles as carriers is a promising cancer treatment avoiding side effects of conventional chemotherapy. We used iron oxide nanoparticles covered by starch derivatives with phosphate groups which bound mitoxantrone as chemotherapeutikum. In this letter we show that a strong magnetic field gradient at the tumour location accumulates the nanoparticles. Electron microscope investigations show that the ferrofluids can be enriched in tumour tissue and tumour cells.
Alexiou
Christoph
C
Klinik und Poliklinik für Hals- Nasen- Ohren- kranke, Universität Erlangen - Nürnberg, Erlangen, Germany. C.Alexiou@web.de
Schmid
Roswitha J
RJ
Jurgons
Roland
R
Kremer
Marcus
M
Wanner
Gerhard
G
Bergemann
Christian
C
Huenges
Ernst
E
Nawroth
Thomas
T
Arnold
Wolfgang
W
Parak
Fritz G
FG
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology*; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry*; D016503:Drug Delivery Systems / Q000379:methods; D008280:Magnetics / Q000627:therapeutic use*; D008942:Mitoxantrone / Q000008:administration & dosage* / Q000737:chemistry*; D053758:Nanoparticles / Q000737:chemistry*; D011817:Rabbits; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D008942:Mitoxantrone